Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed / refractory pancreatic cancer or other CA19-9+malignancies Meeting Abstract
| Authors: | O'Reilly, E. A.; Lohrmann, C.; O'Donoghue, J. A.; Borazanci, E.; Estrella, H.; Teng, R.; Melink, T.; Dorr, K.; Kearns, C.; Peterson, M.; Ostrowski, J.; Gutheil, J.; Maffuid, P. W.; Lewis, J. S.; Weber, W. |
| Abstract Title: | Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed / refractory pancreatic cancer or other CA19-9+malignancies |
| Meeting Title: | 109th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 78 |
| Issue: | 13 Suppl. |
| Meeting Dates: | 2018 Apr 14-18 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2018-07-01 |
| Language: | English |
| ACCESSION: | WOS:000468818900129 |
| DOI: | 10.1158/1538-7445.Am2018-ct140 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CT140 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
